Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | F11 | P03951 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 7/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252706 | 0.85 | CA12 (0.54) | CA12CA9F11FLT3PDGFRB | |
| SCHEMBL29487486 | 0.85 | CA12 (0.54) | CA12CA9F11FLT3PDGFRB | |
| SCHEMBL25903990 | 0.85 | GAA (0.50) | CA12CA9F11FLT3PDGFRB | |
| SCHEMBL4290533 | 0.85 | CA12 (0.53) | CA12CA9F11CA1CA3 | |
| SCHEMBL28299982 | 0.83 | CA12 (0.52) | CA12CA9F11FLT3PDGFRB | |
| SCHEMBL25904005 | 0.81 | CDK4 (0.50) | CA12CA9F11CA1CA3 | |
| SCHEMBL4293404 | 0.81 | HSD17B1 (0.56) | CA12CA9F11CA1CA3 | |
| SCHEMBL4288324 | 0.77 | CA12 (0.52) | CA12CA9F11CA1CA3 | |
| SCHEMBL6031111 | 0.77 | CA12 (0.62) | CA12CA9F11CA1CA3 | |
| SCHEMBL21789054 | 0.76 | CA12 (0.56) | CA12CA9F11ABL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114984055-A | Periplaneta americana intestinal bacteria metabolite extract, pharmaceutical composition and application of pharmaceutical composition in preparation of drugs for treating cardiovascular and cerebrovascular diseases | 天津中医药大学 | 2022-09-02 | — | — | CN | claimed |
| CN-107602463-B | Synthesis method of 6-hydroxy-2 (1H) -quinolinone | 浦拉司科技（上海）有限责任公司 | 2020-04-24 | — | — | CN | claimed |
| CN-102816116-B | Synthetic method of 6-hydroxyl-2(1H)-quinolinone compound | UNIV ZHEJIANG TECHNOLOGY | 2014-03-26 | — | — | CN | claimed |
| CN-102816116-A | Synthetic method of 6-hydroxyl-2(1H)-quinolinone compound | UNIV ZHEJIANG TECHNOLOGY | 2012-12-12 | — | — | CN | claimed |
| CN-102424669-A | Preparation method of 6-hydroxy-2 (1H) -quinolinone compound | Chizhou fangda science and technology co ltd | 2012-04-25 | — | — | CN | claimed |
| EP-1613599-B1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | claimed |
| EP-1791820-B1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | claimed |
| US-20060105410-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | claimed |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | claimed |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1650200-A1 | SULFONATE COMPOUND AND FLUORESCENT PROBE USING THE SAME | Osaka Industrial Promotion Organization (JP) | 2006-04-26 | — | — | EP | claimed |
| EP-1556049-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004017974-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| JP-5304973-A | — | — | None | — | — | JP | disclosed |
| JP-6293770-A | — | — | None | — | — | JP | disclosed |
| JP-2053790-A | — | — | None | — | — | JP | disclosed |
| JP-S5645414-A | PHOSPHODIESTERASE INHIBITOR | OTSUKA PHARMACEUT CO LTD | 1981-04-25 | — | — | JP | disclosed |
| US-4234585-A | ANTIALLERGENS, HYPOTENSIVE | BOEHRINGER MANNHEIM GMBH (DE) | 1980-11-18 | — | — | US | disclosed |
| EP-0006506-A1 | Carbostyrile derivatives, processes for their preparation and pharmaceutical compositions containing them | Roche Diagnostics GmbH (DE) | 1980-01-09 | — | — | EP | disclosed |
| EP-0003771-A1 | Carbostyrile derivatives, their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1979-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105410-A1 | Sulfonate compound and fluorescent probe using the same | BRS3, NCOA3, NR4A3 | CA12 355/4885CA9 438/4885F11 2249/4885 |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3A | CA12 4223/4885CA9 2011/4885F11 4400/4885 |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | SLCO1B3, CBR3, SLCO2B1 | CA12 91/4885CA9 67/4885F11 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.